Michael Davidson, NewAmsterdam Pharma CEO (Caladrius)
January 17, 2023 10:12 AM EST
R&D

NewAms­ter­dam notch­es an­oth­er win in res­ur­rec­tion of Am­gen car­dio drug

Kyle LaHucik

Senior Reporter

A Dutch biotech loaded with hun­dreds of mil­lions of dol­lars to res­ur­rect an old Am­gen drug has tout­ed an­oth­er mid-stage win for the cho­les­terol-low­er­ing as­set …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times